Ang YLE - Search Results

1

Development of PARP inhibitors in gynecological malignancies.

Ang YLE, Tan DSP. Ang YLE, et al. Curr Probl Cancer. 2017 Jul-Aug;41(4):273-286. doi: 10.1016/j.currproblcancer.2017.02.008. Epub 2017 Mar 14. Curr Probl Cancer. 2017. PMID: 28583748 Review.

2

Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer.

Lim JSJ, Wong ALA, Ow SGW, Ngoi NYL, Chan GHJ, Ang YLE, Chong WQ, Lim SE, Lim YW, Lee M, Choo JRE, Tan HL, Yong WP, Soo RA, Tan DSP, Chee CE, Sundar R, Yadav K, Jain S, Wang L, Tai BC, Goh BC, Lee SC. Lim JSJ, et al. Among authors: ang yle. Clin Cancer Res. 2022 Jun 1;28(11):2248-2256. doi: 10.1158/1078-0432.CCR-21-4179. Clin Cancer Res. 2022. PMID: 35363275 Clinical Trial.

3

A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours.

Ang YLE, Ho GF, Soo RA, Sundar R, Tan SH, Yong WP, Ow SGW, Lim JSJ, Chong WQ, Soe PP, Tai BC, Wang L, Goh BC, Lee SC. Ang YLE, et al. BMC Cancer. 2020 Nov 17;20(1):1118. doi: 10.1186/s12885-020-07616-4. BMC Cancer. 2020. PMID: 33203399 Free PMC article. Clinical Trial.

4

Best practice in the treatment of advanced squamous cell lung cancer.

Ang YL, Tan HL, Soo RA. Ang YL, et al. Ther Adv Respir Dis. 2015 Oct;9(5):224-35. doi: 10.1177/1753465815581147. Epub 2015 Apr 22. Ther Adv Respir Dis. 2015. PMID: 25902866 Free article. Review.

5

Translating gastric cancer genomics into targeted therapies.

Ang YL, Yong WP, Tan P. Ang YL, et al. Crit Rev Oncol Hematol. 2016 Apr;100:141-6. doi: 10.1016/j.critrevonc.2016.02.007. Epub 2016 Feb 18. Crit Rev Oncol Hematol. 2016. PMID: 26947813 Free article. Review.

6

Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer.

Ang YL, Lim JS, Soo RA. Ang YL, et al. Onco Targets Ther. 2016 May 30;9:3187-95. doi: 10.2147/OTT.S84356. eCollection 2016. Onco Targets Ther. 2016. PMID: 27313464 Free PMC article. Review.

7

Scalp cooling therapy for chemotherapy-induced hair loss in patients with breast or gynecological cancers-an Asian tertiary institution experience.

Lee VGH, Loh J, Hui F, Sundar R, Tan B, Lee MC, Lin HY, Ong LC, Visvanadan N, Ow SGW, Wong ALA, Chan GHJ, Lim SE, Lim YW, Tan DSP, Ang Y, Choo J, Lee MXW, Ngoi NYL, Lee SC, Paxman R, Parker A, Lee YM, Lim JSJ. Lee VGH, et al. Support Care Cancer. 2024 Nov 1;32(11):762. doi: 10.1007/s00520-024-08940-2. Support Care Cancer. 2024. PMID: 39482416

8

Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.

Huang Y, Zhao JJ, Soon YY, Kee A, Tay SH, Aminkeng F, Ang Y, Wong ASC, Bharwani LD, Goh BC, Soo RA. Huang Y, et al. Cancers (Basel). 2023 May 12;15(10):2733. doi: 10.3390/cancers15102733. Cancers (Basel). 2023. PMID: 37345072 Free PMC article.

9

Has the Ship Sailed on Second-Generation ALK Tyrosine Kinase Inhibitors in the Post-Crizotinib Setting?

Ang YLE, Soo RA. Ang YLE, et al. J Thorac Oncol. 2023 Dec;18(12):1621-1624. doi: 10.1016/j.jtho.2023.09.1438. J Thorac Oncol. 2023. PMID: 37993214 Free article. No abstract available.

10

Phase II study of trifluridine/tipiracil in metastatic breast cancers with or without prior exposure to fluoropyrimidines.

Lim JSJ, Ow SGW, Wong ALA, Lee MXW, Chan GHJ, Low JL, Sundar R, Choo JRE, Chong WQ, Ang YLE, Tai BC, Lee SC. Lim JSJ, et al. Among authors: ang yle. Eur J Cancer. 2023 Nov;193:113311. doi: 10.1016/j.ejca.2023.113311. Epub 2023 Aug 25. Eur J Cancer. 2023. PMID: 37717281

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

23 results

Search Page

Filters